Vanda Pharmaceuticals Inc. (VNDA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Vanda Pharmaceuticals Inc. (VNDA) closed at USD 4.22 on 2026-10-14, a change of -24.4 % over the past year, with a market capitalization of USD 256.36M.

Vanda Pharmaceuticals Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Vanda Pharmaceuticals Inc. key figures

Previous close

USD 4.22 (2026-10-14)

1-year change

-24.4 %

Market cap

USD 256.36M

Enterprise value

USD 109.16M

P/E ratio (trailing)

-0.92

P/E ratio (forward)

21.20

EPS (trailing)

-4.63

EPS (forward)

0.20

PEG ratio

2.23

Price to book

1.16

Revenue growth

-3.9 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

8.08

Employees

533

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Vanda Pharmaceuticals Inc. and compare it with other stocks.